February 4, 2021 by Chain Drug Review
Kenneth Frazier, Merck
Business, Leading Headlines, Pharmacy, Supplier News
KENILWORTH, N.J. — Merck announced that Kenneth Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021. Frazier will continue to serve on Merck’s board of directors as executive chairman, for a transition period to be determined by the board. The Merck board of directors has unanimously elected Robert M. Davis,
August 15, 2017 by CDR Blog and Chain Drug Review
Brian Krzanich, Doug McMillon, Kenneth Frazier, Kevin Plank, President Donald Trump, protests in Charlottesville, Walmart
CDR Blog
Add Walmart’s Doug McMillon to the list of chief executives concerned about President Donald Trump’s response to the violent protests in Charlottesville, Va. In a statement posted Tuesday on a Walmart website, McMillon wrote, “The role we play in communities around the country to build a more diverse and inclusive society is more critical than
August 14, 2017 by CDR Blog and Chain Drug Review
Kenneth Frazier, Merck, President Donald Trump, protests in Charlottesville
CDR Blog
Amid the shakeout from President Donald Trump’s statements on the violence erupting in protests in Charlottesville, Va., Merck & Co. chairman and CEO Kenneth Frazier said he’s leaving the President’s American Manufacturing Council. Frazier said in a statement posted on Twitter early Monday morning, “I am resigning from the President’s American Manufacturing Council. Our country’s
March 10, 2016 by Chain Drug Review
Kenneth Frazier, Merck, Merck Manufacturing Division, Sanat Chattopadhyay, Willie Deese
Pharmacy, Supplier News
KENILWORTH, N.J. — Sanat Chattopadhyay has been promoted to executive vice president and president of the Merck Manufacturing Division (MMD). Plans call for Chattopadhyay, currently senior vice president of Global Manufacturing Operations (Human Health), to start in the new position on April 1. He succeeds Willie Deese who will retire on June 1 after 12 years
April 17, 2015 by John Schultz and Chain Drug Review
Ian Read, John Castellani, Kenneth Frazier, Pharmaceutical Research and Manufacturers of America, PhRMA
Leading Headlines, Supplier News
WASHINGTON — John Castellani, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), plans to retire next year. PhRMA said Thursday that Castellani’s retirement is slated to go into effect Jan. 1, 2016. “Representing the biopharmaceutical industry has been one of the most rewarding experiences of my career, and I am